Artivion (NYSE:AORT) Research Coverage Started at JMP Securities

JMP Securities began coverage on shares of Artivion (NYSE:AORT) in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $33.00 price objective on the stock.

A number of other equities analysts also recently weighed in on the stock. Needham & Company LLC reissued a “buy” rating and issued a $30.00 price target on shares of Artivion in a report on Friday, September 27th. Oppenheimer boosted their price objective on Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Lake Street Capital increased their target price on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, July 2nd. Finally, Stifel Nicolaus boosted their target price on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, September 13th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Artivion has an average rating of “Buy” and an average target price of $30.60.

Artivion Stock Performance

Shares of AORT stock opened at $26.47 on Wednesday. The company has a current ratio of 5.63, a quick ratio of 4.04 and a debt-to-equity ratio of 1.07. The firm has a fifty day simple moving average of $25.90 and a two-hundred day simple moving average of $24.66. The firm has a market capitalization of $1.10 billion, a PE ratio of -110.29 and a beta of 1.74. Artivion has a 12 month low of $12.16 and a 12 month high of $29.24.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.04. Artivion had a negative net margin of 2.22% and a positive return on equity of 3.81%. The firm had revenue of $98.02 million for the quarter, compared to the consensus estimate of $97.70 million. Analysts forecast that Artivion will post 0.2 EPS for the current fiscal year.

Insider Buying and Selling at Artivion

In other Artivion news, Director Anthony B. Semedo sold 9,709 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total transaction of $242,627.91. Following the completion of the sale, the director now directly owns 34,159 shares in the company, valued at $853,633.41. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Artivion news, SVP Jean F. Holloway sold 3,167 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $26.55, for a total transaction of $84,083.85. Following the completion of the transaction, the senior vice president now owns 161,932 shares of the company’s stock, valued at $4,299,294.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Anthony B. Semedo sold 9,709 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $24.99, for a total value of $242,627.91. Following the completion of the sale, the director now directly owns 34,159 shares of the company’s stock, valued at $853,633.41. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 37,109 shares of company stock worth $951,935 over the last ninety days. Insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company grew its holdings in Artivion by 3.2% in the second quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company’s stock worth $392,000 after purchasing an additional 481 shares during the period. GAMMA Investing LLC grew its position in shares of Artivion by 38.6% during the 1st quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock valued at $38,000 after acquiring an additional 505 shares during the period. Louisiana State Employees Retirement System raised its holdings in Artivion by 3.1% in the 2nd quarter. Louisiana State Employees Retirement System now owns 19,900 shares of the company’s stock worth $510,000 after purchasing an additional 600 shares during the period. Texas Permanent School Fund Corp lifted its position in Artivion by 2.0% during the first quarter. Texas Permanent School Fund Corp now owns 34,129 shares of the company’s stock valued at $722,000 after purchasing an additional 677 shares in the last quarter. Finally, nVerses Capital LLC bought a new stake in Artivion during the second quarter valued at about $28,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.